<p>I-Mab NovaBridge Biosciences has filed an application for a proposed dual primary listing of its ordinary shares, with a par value of US$0.0001 per share, on the Main Board of the Hong Kong Stock Exchange. The listing will be accompanied by an initial public offering of the shares on the Hong Kong Stock Exchange. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. I-Mab published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-259310), on October 31, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

IMAB

<p>I-Mab NovaBridge Biosciences has filed for a dual primary listing of its ordinary shares on the Hong Kong Stock Exchange, with an accompanying initial public offering. The shares have a par value of US$0.0001 each. This announcement is for informational purposes and should not be considered financial or legal advice.</p>

I-Mab Files for Dual Primary Listing on Hong Kong Stock Exchange